Taiho Oncology News and Activities

Taiho Oncology is owned by Otsuka Holdings.

Otsuka Holdings is one of the...

• Forbes Global 2000 (#654);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Otsuka Holdings is a company listed under the stock ticker 4578 (JP).

Otsuka Holdings has a direct presence in 11 countries.

Otsuka Holdings has 23 subsidiaries including Araris Biotech, Cambridge Isotope Laboratories and Interpharma.

They are in:

• Pharmaceuticals46%
• Medical Equipment29%
• Other25%

View the org chart displaying its 22 main executives

Most searched biographies at Taiho Oncology

• Peter Melnyk, President & Chief Executive Officer
• Volker Wacheck, Senior Vice President and Head of Clinical Develop...
• Chris Jewell, Senior Vice President and General Counsel

Popular executive movements at Taiho Oncology

• Tim Whitten, President and Chief Executive Officer, has left the company  (posted on January 30 2026).
• Peter Melnyk, who was President & Chief Operating Officer, is promoted to President & Chief Executive Officer  (posted on January 30 2026).
• Peter Melnyk has joined the company as President & Chief Operating Officer  (posted on January 21 2026).

Create your alert
to follow the executive moves at Taiho Oncology.

Otsuka Holdings has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Corden Pharma has announced the acquisition of AmbioPharm  (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Taiho Oncology

• Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib f
• Taiho Oncology Announces 14 Presentations, Including Six Oral Presentations, at the 67th American Society of Hematology Annual Meeting and Exposition
• Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
• Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
• Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025
• Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
• Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients wit
• Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
• Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
• Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
• View more press releases Close

Social media about Taiho Oncology

• Taiho Oncology on Wikipedia, Google News & Yahoo Finance
• Taiho Oncology on LinkedIn, X (Twitter) & YouTube